Tufts CSDD's updated 2024 estimate of the direct cost of a Phase 2 or 3 clinical trial puts it at approximately $40,000 per day, with a single day of delay now worth roughly $500,000 to $800,000 in lost prescription drug or biologic sales, a dramatic increase from the outdated $4 to $5 million per-day-of-delay industry estimate that had circulated since 1993 ( [97] ) ( [98] ), which Tufts characterized as "a gross misestimation for more than 25 years." Every added day spent building a more representative recruitment pipeline therefore carries a real, quantifiable opportunity cost that sponsors must weigh against the scientific and regulatory value of representative data, a tension the still-unfinished Diversity Action Plan guidance leaves unresolved for 2026 planning purposes
We designed a peptide inhibitor prototype, named p53 TAD PEP, comprising 16 amino acids corresponding to residues 4257 of the p53 TAD sequence (Figure
Some of the urine analytes were non-specifically elevated in both IC/BPS and OAB, but some were specific to the respective groups, indicating their common and distinct inflammation-related pathomechanisms, respectively
GHK-Cu stands out as my top recommendation for addressing loose skin during weight loss